Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?

被引：0
作者：
Takeshi Yamada
Yoshiyuki Yamamoto
Toshikazu Moriwaki
Ichisnosuke Hyodo
机构：
[1] University of Tsukuba,Department of Gastroenterology
来源：
Journal of Gastroenterology | 2016年 / 51卷
关键词：
Gastric Cancer; Trastuzumab; Irinotecan; Advanced Gastric Cancer; Fluoropyrimidine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：506 / 507
页数：1
相关论文
共 7 条
[1]  
Lam L(2012)Challenges in the clinical utility of the serum test for HER2 ECD Biochim Biophys Acta 1826 199-208
[2]  
McAndrew N(2015)Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy J Gastroenterol 50 955-961
[3]  
Yee M(2012)Patient heterogeneity and allocation bias: how should they be reported in clinical trials of chemotherapy for advanced gastric cancer? Gastric Cancer 15 115-117
[4]  
Zhou J(undefined)undefined undefined undefined undefined-undefined
[5]  
Peng Z(undefined)undefined undefined undefined undefined-undefined
[6]  
Liu Y(undefined)undefined undefined undefined undefined-undefined
[7]  
Hyodo I(undefined)undefined undefined undefined undefined-undefined
1